ESR1 and breast carcinoma: The use of most of the anticancer drugs, including tamoxifen, is limited due to the drug resistance by breast cancer cells, which is a serious problem in treating breast cancer patients with positive ERα expression, as evidences showed that the expression of estrogen receptor (ERα) determined the response of breast cancer cells to tamoxifen [24–26].